USFDA granted approval to Aurobindo Pharma for Flucytosine Capsules

Aurobindo Pharma received its final approval from the US Food & Drug Administration (USFDA) to manufacture and market Flucytosine Capsules, 250 mg and 500 mg.

Flucytosine Capsules are used for the treatment of serious infections caused by susceptible strains of Candida and Cryptococcus. The Capsules are a generic version of Bausch Health’s Ancobon Capsules and the capsules will be launched in June 2020.

A total of 429 ANDA approvals has been granted to Aurobindo (401 Final approvals including 23 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

  • Related Posts

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26. Zydus Lifesciences reported a rise in…

    Chemists strike on May 20: Reasons behind today’s all-India strike

    While major pharmacy chains and government medical outlets will remain operational, the strike highlights significant tensions within the industry that could impact access to medications nationwide. The All India Organisation…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Zydus Lifesciences Q4FY26 net profit rises 9%

    Chemists strike on May 20: Reasons behind today’s all-India strike

    Chemists strike on May 20: Reasons behind today’s all-India strike

    AbbVie loses patent plea for Hep C drug

    AbbVie loses patent plea for Hep C drug

    GSK’s Calpol a well-known trademark: High Court

    GSK’s Calpol a well-known trademark: High Court

    3 arrested for allegedly posing as doctors using forged MBBS degrees

    3 arrested for allegedly posing as doctors using forged MBBS degrees

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures